6-K - IceCure Medical Ltd | StockGist

AI Analysis

AI-generated analysis. Always verify with the original filing.

IceCure Medical Ltd. announced a registered direct offering of 8,000,000 ordinary shares at $0.50 per share and a concurrent private placement of Series B and Series C warrants to purchase up to 16,000,000 ordinary shares, with expected gross proceeds of approximately $4.0 million. The company intends to use the net proceeds for working capital and other general corporate purposes.

Key Takeaways

1The company entered into a registered direct offering for 8,000,000 ordinary shares at a purchase price of $0.50 per share.

2Gross proceeds from the offering are expected to be approximately $4.0 million before deducting placement agent fees and offering expenses.

3In a concurrent private placement, the company will issue unregistered Series B warrants to purchase up to 8,000,000 ordinary shares and Series C warrants to purchase up to 8,000,000 ordinary shares.

4The warrants have an exercise price of $0.55 per share, are exercisable immediately, with Series B warrants expiring five years from issuance and Series C warrants expiring one year from issuance.

5The closing of the offering is expected to occur on or about March 27, 2026, subject to customary closing conditions.

6A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering.

Current Report Details

Event Type

Securities Issuance

Disclosure

Voluntary

Variant

6-K

Items Reported

6-K

Current Report on Form 6-K

Securities Issuance

Exhibits (7)

10.1

FORM OF SECURITIES PURCHASE AGREEMENT, DATED AS OF MARCH 26, 2026, BY AND BETWEEN THE COMPANY AND THE PURCHASER PARTIES THERETO

10.2

PLACEMENT AGENCY AGREEMENT, DATED AS OF MARCH 26, 2026, BY AND BETWEEN THE COMPANY AND A.G.P./ALLIANCE GLOBAL PARTNERS

4.1

FORM OF SERIES B WARRANT

4.2

FORM OF SERIES C WARRANT

5.1

OPINION OF SULLIVAN & WORCESTER TEL AVIV (HAR-EVEN & CO.)

6-K

REPORT OF FOREIGN PRIVATE ISSUER

99.1

PRESS RELEASE DATED MARCH 26, 2026, TITLED "ICECURE ANNOUNCES PRICING OF $4.0 MILLION REGISTERED DIRECT OFFERING AND CONCURRENT PRIVATE PLACEMENT."